September 26, 2018 09:43 AM EDT
Financing

As­traZeneca-backed En­ta­sis Ther­a­peu­tics joins the IPO class of 2018 with a weak de­but price

John Carroll

Editor & Founder

En­ta­sis Ther­a­peu­tics has made it to Nas­daq.

The an­tibi­otics group — a spin­out from As­traZeneca — had a dis­ap­point­ing de­but, pric­ing shares at $15 apiece …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times